Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Qualigen Therapeutics Inc (Qualigen) develops therapeutics for the treatment of cancer and infectious diseases. The company's cancer therapeutics pipeline includes QN-247 and RAS-F. QN-247 is a (DNA) coated gold nanoparticle cancer drug candidate to target various types of cancer. QN-247 is a nanoparticle coating technology that is similar to the core nanoparticle coating technology used in blood-testing diagnostic products. QN-165 is a drug candidate for treating viral-based infectious diseases. RAS-F is a family of rat sarcoma virus (RAS) oncogene protein-protein interaction inhibitor small molecules for preventing mutated RAS genes’ proteins from binding to their effector proteins and preventing binding tumor growth, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device candidate for removal from circulating blood of precisely targeted tumor-produced and viral compounds. Qualigen is headquartered in Los Angeles, California, the US.
Headquarters
United States of America
Address
1880 Century Park E Ste 1000, Los Angeles, California, 90067-1623
Website
www.qualigeninc.com
Telephone
1 310 2031000
No of Employees
4
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
QLGN (NASD)
EPS
XYZ
Net Income (2022)
XYZ
28%
(2022 vs 2021)
Market Cap*
$1.9M
Net Profit Margin (2020)
XYZ
0.0%
(2022 vs 2021)
* As of and is in US$
Products and Services
| Products |
|---|
| QN-302 |
| QN-247 |
| QN-165 |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Divestiture | In July, the company sold the FastPack diagnostics business to Chembio Diagnostic Inc. |
| 2022 | Acquisitions/Mergers/Takeovers | In June, the company acquired a majority stake in NanoSynex Ltd., a developer of next generation diagnostics technology. |
| 2021 | Contracts/Agreements | In March, the company entered into an option agreement with the University College London to advance development of anticancer drug candidate AS1411-GNP. |
Competitor Comparison
| Key Parameters | Qualigen Therapeutics Inc | AbbVie Inc | Abbott Laboratories | Abeona Therapeutics Inc |
|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America |
| City | Los Angeles | North Chicago | Abbott Park | Cleveland |
| State/Province | California | Illinois | Illinois | Ohio |
| No. of Employees | 4 | 50,000 | 114,000 | 84 |
| Entity Type | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Michael S. Poirier | Director; Chief Executive Officer; Chairman | Executive Board | 2020 | 67 |
| Amy Broidrick | Director; Chief Strategy Officer; President | Executive Board | 2020 | 64 |
| Christopher L. Lotz | Vice President; Secretary; Chief Financial Officer | Senior Management | 2002 | 57 |
| Tariq Arshad | Senior Vice President; Chief Medical Officer | Senior Management | 2021 | 52 |
| Benedict M. Abugan | Vice President; Head - Diagnostics and Corporate Communications | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer